During the third fiscal quarter, according to Tuesday’s news release, Jabil successfully transitioned additional sites from Johnson & Johnson Medical Devices Companies (JJMDC) as part of the previously announced strategic collaboration between the companies.

Fourth-quarter outlook revealed that net revenue was to come in between $6.3 and $6.9 billion, with U.S. GAAP operating income forecast for between $169 and $235 million, while diluted earnings per share is foreseen between 47 cents and 71 cents.